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Abstract: Liquid chromatography coupled with high resolution mass spectrometry
(LC-HRESMS)-assisted metabolomic profiling of two sponge-associated actinomycetes,
Micromonospora sp. UR56 and Actinokineospora sp. EG49, revealed that the co-culture of these
two actinomycetes induced the accumulation of metabolites that were not traced in their axenic
cultures. Dereplication suggested that phenazine-derived compounds were the main induced
metabolites. Hence, following large-scale co-fermentation, the major induced metabolites were
isolated and structurally characterized as the already known dimethyl phenazine-1,6-dicarboxylate (1),
phenazine-1,6-dicarboxylic acid mono methyl ester (phencomycin; 2), phenazine-1-carboxylic
acid (tubermycin; 3), N-(2-hydroxyphenyl)-acetamide (9), and p-anisamide (10). Subsequently,
the antibacterial, antibiofilm, and cytotoxic properties of these metabolites (1–3, 9, and 10) were
determined in vitro. All the tested compounds except 9 showed high to moderate antibacterial and
antibiofilm activities, whereas their cytotoxic effects were modest. Testing against Staphylococcus
DNA gyrase-B and pyruvate kinase as possible molecular targets together with binding mode studies
showed that compounds 1–3 could exert their bacterial inhibitory activities through the inhibition of
both enzymes. Moreover, their structural differences, particularly the substitution at C-1 and C-6,
played a crucial role in the determination of their inhibitory spectra and potency. In conclusion,
the present study highlighted that microbial co-cultivation is an efficient tool for the discovery of
new antimicrobial candidates and indicated phenazines as potential lead compounds for further
development as antibiotic scaffold.
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1. Introduction
Natural products derived from marine microbes play a pivotal role in drug discovery and
development due to their diverse molecular and chemical scaffolds, which cannot be matched by
any synthetic or combinatorial libraries [1]. Marine-sponge-associated actinomycetes have recently
been used to produce a multitude of new bioactive compounds with novel molecular scaffolds and
potent pharmacological activities such as antibacterial, antifungal, antiparasitic, immunomodulatory,
anti-inflammatory, antioxidant, and anticancer activities [2–5]. However, searching for new and
promising bioactive secondary metabolites from marine microbes is becoming a serious challenge due
to the increasing rate of rediscovery of known secondary metabolites [6,7]. On the other hand, genomic
work has revealed that definite groups of bacteria and fungi have huge numbers of silent biosynthetic
gene clusters (BGCs) that encode for secondary metabolites that are not traced under normal laboratory
conditions [8,9]. Microbial competition for space and nutrition are considered eventual routes for the
induction of bioactive metabolites, mainly antimicrobial agents [10]. Several protocols have been used
to trigger such cryptic biosynthetic pathways. One of these protocols involves co-cultivation or the
so-called mixed fermentation of two or more microorganisms in a single culture flask, which results in
the production of antimicrobial secondary metabolites [11–13]. Recently, we reported the production of
new antitumor agents, saccharomonosporine A and convolutamydine F, by the co-fermentation of two
marine-sponge-associated actinomycetes, Dietzia sp. UR66 and Saccharomonospora sp. UR22, obtained
from Callyspongia siphonella [14]. A chlorinated benzophenone pestalone that showed potent antibiotic
activity was sourced from the co-cultivation of two marine-associated fungi,α-proteobacterium CNJ-328
and Pestalotia sp. CNL-365 [15]. The induction of cryptic pulicatin derivatives that exhibit potent
antifungal effects through the microbial co-culture of Pantoea agglomerans with Penicillium citrinum was
recently reported [16]. Finally, the induced production of emericellamides A and B obtained from
a co-fermentation of the marine-associated fungus Emericella sp. CNL-878 and the marine derived
bacterium Salinispora arenicola was reported [17].
Phenazine compounds are heterocyclic nitrogenous compounds that consist of two benzene rings
attached through two nitrogen atoms and substituted at different sites of the core ring system. Phenazine
derivatives have been found to show a wide range of biological activities, including antibacterial,
antiviral, antitumor, antimalarial, and antiparasitic activities [18,19]. They have been isolated in large
amounts from terrestrial bacteria such as Pseudomonas, Streptomyces, and other genera from marine
habitats [20]. The iminophenazine clofazimine is an example of a successful phenazine derivative,
having been approved by the FDA for the treatment of leprosy and drug-resistant Mycobacterium
tuberculosis strains [21,22]. Another example of a phenazine is bis-(phenazine-1-carboxamide),
which acts as a strong cytotoxin and represents an attractive class of anticancer drugs [23]. In an
earlier work, we found that Actinokineospora sp. EG49 was able to induce Nocardiopsis sp. RV163 to
produce 1,6-dihydroxyphenazine upon co-cultivation [24]. On the other hand, Micromonospora sp.
are widespread actinomycetes and prolific producers of diverse antibiotics [25,26]. Consequently,
we decided to extend our co-cultivation trials on both marine-derived Actinokineospora sp. EG49
and Micromonospora sp. UR56 in order to induce the production of further antibacterial metabolites,
which were also found to be of the phenazine class. Based on earlier reports on the biological activities
of this class of compounds, we suggested both DNA gyrase B (Gyr-B) and pyruvate kinase (PK) to be
the possible molecular targets of their antibacterial activity. The working outline of the present study is
illustrated in Figure 1.
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Figure 1. Outline of the procedure used in the present study.
2. Results and Discussion
2.1. Metabolomic Profiles of the Axenic and Co-Culture Extracts
The chemical profiles of the actinomycetes Micromonospora sp. UR56 and Actinokineospora sp. EG49
were investigated via liquid chromatography coupled with mass spectrometry (LC-HRMS) analysis
after their fermentations (axenic and co-fermentation). The metabolomic profile of the co-culture
extract displayed the induction of diverse metabolites from different chemical classes compared to
those of the two axenic cultures (Figure 2, Supplementary Figure S32, and Supplementary Table S3).
Twelve metabolites were putatively identified in the Micromonospora sp. UR56-derived extract,
where phenazine derivatives were found to prevail (Figure 2; Figure 3, Supplementary Figure S30).
Most of these dereplicated phenazines e.g., phenazine-1-carboxylic acid (3), aestivophoenin c (8),
and methyl saphenate (4) have been reported to possess antimicrobial and cytotoxic properties [27].
The remaining identified compounds were found to belong to the N-containing and polyketide classes.
Within the axenic Actinokineospora sp. EG49 culture, no phenazine derivatives were traced in the
LC-HRMS analysis of the extract. Additionally, its chemical profile revealed poor diversity, with a few
identified N-containing and polyketide metabolites (Supplementary Figure S31 and Supplementary
Table S2). On the other hand, the mixed fermentation of both actinomycetes induced Micromonospora sp.
UR56 to accumulate diverse phenazine derivatives (1–8) (Figure 2). Such induction could be due to
environmental competition or chemical defense mechanisms [10]. Based on the metabolomic profiling of
the co-culture, the major induced metabolites (1–3, 9, and 10) were targeted and isolated using Sephadex
LH20 followed by silica gel column chromatography, and identified using different spectroscopic
approaches. Subsequently, they were subjected to antibacterial, antibiofilm, and cytotoxicity testing.
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Figure 3. Identified phenazine derivatives in the axenic Micromonospora sp. UR56 culture,
and after its co-culture with Actinokineospora sp. EG49. 1: dimethyl phenazine-1,6-dicarboxylate,
2: phencomycin, 3: phenazine-1-carboxylic acid, 4: methyl saphenate, 5: 1-hydroxy methyl-6-carboxy
phenazine, 6: griseolutic acid, 7: griseolutin A, 8: aestivophoenin C, 9: N-(2-hydroxyphenyl)-acetamide,
and 10: p-anisamide.
2.2. Bioactivity Testing
2.2.1. Antibacterial Activity
Based on earlier reports on their antibacterial potential, phenazine-derived compounds
have proven to be an interesting chemical scaffold for the development of new antibacterial
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agents [27]. Therefore, all isolated compounds were evaluated against Staphylococcus aureus ATCC9144,
Bacillus subtilis ATCC29212, Pseudomonas aeruginosa ATCC27853, and Escherichia coli ATCC25922
(Table 1). Compounds 3 and 10 displayed potent antibacterial activity against P. aeruginosa with growth
inhibition of 94% and 70%, respectively, while compounds 1, 2, and 9 showed considerable antibacterial
activity against S. aureus with growth inhibition of 47%, 69%, and 53%, respectively (Table 1). Based on
these results together those previously reported [27], we concluded that the phenazine-1-carboxylic
acid scaffold is essential for antibacterial activity against Gram-negative bacteria and produces no
observable activity towards Gram-positive ones. Although the addition of another carboxylic acid or
carboxyl ester at C-6 significantly decreased the inhibitory activity against Gram-negative bacteria,
it converted these phenazine derivatives to be active against Gram-positive strains (Figure 4).
Table 1. Growth inhibition % of 1–3, 9, and 10 at 15 µM against different bacterial strains.
Tested Compounds Staphylococcus aureus Bacillus subtilis Escherichia coli Pseudomonas aeruginosa
1 57.19 ± 1.2 19.61 ± 1.5 9.93 ± 1.3 23.41 ± 1.7
2 68.87 ± 0.8 32.13 ± 1.3 11.15 ± 1.4 23.25 ± 2.2
3 NA 1.69 ± 1.2 24.34 ± 1.8 94.17 ± 2.8
9 1.1 ± 0.9 NA NA 4.74 ± 1.6
10 53.17 ± 1.2 42.16 ± 1.9 19.27 ± 2.5 70.23 ± 1.1
Gentamicin 99.1 ± 0.7 97 ± 1.6 99 ± 0.6 99.7 ± 0.2
NA: no activity.
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2.2.2. Antibiofilm Activity
To further evaluate the inhibitory activities of the isolated metabolites (1–3, 9, and 10), their
antibiofilm potentials against S. aureus, B. subtilis, E. coli, and P. aeruginosa were determined. Compounds
3 and 10 displayed potent ntibiofilm activity against P. aerug nosa with % inhibition rates of 94% an
73%, respectively, while compounds 1, 2, and 9 showed mild to moderat inhibitory activity against
E. coli with % inhibition ranges of 34–54%. Compounds 1 and 2 both showed potent to moderate
inhibitory ctivity against S. aureus with % inhibition rates of 50% and 75%, respectively (Table 2).
Similar to the anti acterial results, the presenc of carboxylic ac ds on both C-1 and C-6 of the ph nazine
ring system decreased the antibiofilm effect towards Gram-negative strains, but made these derivatives
active ag inst Gram-positive on s, particularly, S. aur us (Figure 4).
2.2.3. Cytotoxic Activity
The five induced compounds (1–3, 9, and 10) were additionally tested for their cytotoxic activity
against four human cancer cell lines (Table 3). Only compound 9 was able to induce moderate
cytotoxicity towards the tested cell lines, with IC50 values ranging from 10 to 36 µM. Regarding the
activity of phenazine derivatives (1–3), compound 2 was found to be the most active against all tested
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cell lines. Previous studies have suggested that phenazine-related compounds can exert significant
cytotoxic activities through the inhibition of topoisomerase enzymes [28–30].
Table 2. Antibiofilm activity of 1–3, 9, and 10 at 2 µM against different bacterial strains.
Tested Compounds S. aureus B. subtilis E. coli P. aeruginosa
1 50.26 ± 0.4 12.10 ± 3.2 36.66 ± 2.9 18.36 ± 0.9
2 75.10 ± 2.4 18.65 ± 1.6 54.07 ± 2.5 22.28 ± 1.5
3 NA NA 54.67 ± 1.4 93.98 ± 2.2
9 11.47 ± 2.9 4.91 ± 1.8 34.55 ± 2.6 7.39 ± 1.9
10 61.20 ± 3.7 20.29 ± 1.1 57.47 ± 3.1 73.52 ± 1.3
NA: no activity.
Table 3. Cytotoxic activity of isolated compounds 1–3, 9, and 10 at 2 µM.
Tested Compounds WI38 HCT116 HePG-2 MCF7
1 63.18 ± 3.6 85.04 ± 3.9 92.06 ± 4.7 >100
2 76.30 ± 3.9 60.81 ± 3.5 76.11 ± 3.9 82.24 ± 4.4
3 51.22 ± 3.2 91.27 ± 4.6 >100 >100
9 36.47 ± 2.3 14.56 ± 1.2 10.16 ± 0.9 12.65 ± 1.1
10 >100 >100 >100 >100
Doxorubicin 6.72 ± 0.5 5.23 ± 0.3 4.50 ± 0.2 4.17±0.2
2.2.4. In Vitro Enzyme Assay
DNA gyrase is a topoisomerase-type enzyme present exclusively in bacterial cells. Inhibition
of its subunit A (Gyr-A) leads to cell death by trapping the gyrase–DNA complex and preventing
DNA replication. On the other hand, inhibition of Gyr-B blocks ATPase activity and thus deprives
the cell of the energy source needed for DNA replication [31]. Gyr-B as a molecular target offers
an opportunity to avoid cross-resistance to the well-known Gyr-A inhibitors, quinolones. Several
phenazine and acridine derivatives have been reported to be topoisomerase I and II inhibitors in
human cancer cells [28–30]. The characteristic planar structure of this class of compounds directs
them to interact with the ATP-binding domains of the enzymes (ATPase pocket) [28]. On the other
hand, PK is known to be a critical enzyme in catalyzing the final step of glycolysis, which involves the
transfer of a phosphoryl group from phosphoenolpyruvate to ADP, producing pyruvate and ATP [32].
Recently, it was identified as a “superhub”, listed among the top 1% of all interacting proteins in
S. aureus and found to be a key regulator of the quorum-sensing system and the biofilm formation
process in staphylococci [33–35]. Considering these points together with the structural similarity of our
compounds (1–3) to previously well-known topoisomerase inhibitors, we selected Staphylococcus DNA
gyrase-B and PK as possible molecular targets to mediate the observed antibacterial and antibiofilm
activities of the induced phenazine derivatives toward S. aureus. In vitro studies (Table 4) showed 1 to
be the most active compound against both Gyr-B and PK, followed by 2 and 3. These finding indicate
a direct link between the substitutions on C-1 and C-6 and the Gyr-B- and PK-inhibitory activities
of this class of metabolites (Figure 3). Although the enzyme-inhibitory activity of compounds 1–3
was convergent, and compound 1 was slightly more active than compound 2 in the enzyme assay
studies, compound 3 was inactive, and 1 was less active than 2 in both inhibitory assays against
S. aureus. These observations could be attributed to the bacterial cell wall permeability, where S. aureus
may permit the diffusion of 2 more easily than 1 and prevent the crossing of compound 1. In the
same manner, P. aeruginosa’s outer membrane may be selective only for compound 3, and hence make
both other phenazines (1 and 2) inactive. According to a previous report [36], small, moderately
lipophilic compounds can cross the Gram-positive bacterial membrane more easily. In contrast,
Gram-negative bacteria, which have porins (hydrophilic channels) in their outer membranes, are more
selective for hydrophilic compounds. The calculated LogP (cLogP) of each compound revealed that
compound 2 had the optimum lipophilicity (cLogP = 1.9), whereas compound 1 was less lipophilic
(cLogP = 1.12) and compound 3 was more lipophilic (cLogP = 2.97) Such differences in lipophilicity
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between compounds 1 to 3 could explain the opposite observations between enzyme inhibition and
antibacterial and antibiofilm activities of compounds 1–3.
Table 4. Calculated interactions and affinities of compounds 1–3 with active-site residues of the
Staphylococcus Gyr-B and PK.
Protein Target Ligand IC50 (µM) *
Binding Energy
(kcal/mol)
Hydrogen
Bonding Interactions
Hydrophobic
Interactions
Gyr-B
1 19.18 ± 1.69 −7.6 ASN-54, GLU-58
ILE-51, VAL-79
PRO-87, ILE-86
ILE-102,
ILE-103
ILE-175
2 21.28 ± 2.36 −7.5 SER-55, ILE-51
ILE-51, VAL-79
PRO-87, ILE-86
ILE-102,
ILE-103
ILE-175
3 27.69 ± 1.08 −7.2 SER-55, ILE-51
ILE-51, VAL-79
PRO-87, ILE-86
ILE-102,
ILE-103
ILE-175
Co-crystallized ligand 0.091 - ASP-81, ASN-54
ILE-51, VAL-79
PRO-87, ILE-86
ILE-102,
ILE-103
ILE-175
PK
1 7.2 ± 0.07 −7.7
SER-362A, SER-362B
THR-366A, THR-353B,
ASN-369A
ALA-358B,
ILE-361B,
LEU-370A
2 9.3 ± 0.03 −7.5 SER-362A, THR-366A,THR-353B, ASN-369A
ALA-358B,
ILE-361B,
LEU-370A
3 22.5 ± 0.04 −6.5 ASN-369B, THR-353A ALA-358A,ILE-361A
Co-crystallized ligand 0.24 - SER-362A, SER-362B,ASN-369B, HIS-365A
ALA-358A,
ALA-358B
ILE-361B,
LEU-370A
* IC50 ± SD (µM).
2.3. Docking Study
The potential binding modes of 1–3 with DNA Gyr-B and pyruvate kinase were investigated by
docking at their active binding sites. Staphylococcus Gyr-B and PK of PDB code (3g7b and 3T0T) were
selected for docking tests since they had optimum resolutions (2.3 Å and 3.1 Å) and are co-crystallized
with their inhibitors. The spheres surrounding the co-crystallized inhibitors were selected as active
sites for docking. All isolated compounds exhibited convergent docking poses (Figure 5) and were
comparable to the co-crystallized Gyr-B inhibitor [37]. The oxygens of both ester groups of 1 on C1
and C6 were hydrogen-bonded to ASN-54, similarly to the co-crystallized Gyr-B ligand, and GLU-58.
These interactions meant that the whole molecule was well-embedded inside the active site pocket,
where it was further stabilized by the hydrophobic interactions between the molecule’s aromatic rings
and ILE-51, VAL-79, PRO-87, ILE-86, ILE-102, ILE-103, and ILE-175. The absence of an ester group in
2 and 3 led them to take a different and less stable orientation inside the binding pocket and hence,
their carboxylic acid moieties interacted from only one side with different amino acid residues via
hydrogen bonds (SER-55 and ILE-51); however, they showed similar hydrophobic interactions to 1.
Unlike the co-crystallized Gyr-B inhibitor, 1–3 did not show any interactions with ASP-81. On the other
hand, 1 and 2 showed similar binding modes in the PK active site, although different from that of 3.
The co-crystallized PK inhibitor [38] fitted perfectly inside the pocket formed between the enzyme’s
A and B subunits (Figure 6). This binding mode was stabilized by six main hydrogen bonds with
SER-362A, SER-362B, ASN-369B, and HIS-365A (A and B notations correspond to PK subunits). These
interacting residues are of particular interest as they are not conserved in human PK, and thus are likely
to further influence the selectivity of the bacterial PK inhibitors. Herein, 1 showed a convergent binding
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mode to the co-crystallized PK inhibitor, where it anchored on one side of the PK active site (Figure 6)
through three hydrogen bonds with SER-362A and SER-362B, similarly to the co-crystallized ligand,
and through an additional hydrogen bond with THR-366A. All these interactions were from the ester
moiety of one side of the molecule; the second ester group on the other side increased the molecular
stability inside the binding site through hydrogen bonding to THR-353B and ASN-369A. Additionally,
the aromatic planar structure of 1 was sandwiched between two hydrophobic surfaces inside the
binding pocket, where it interacted via hydrophobic interactions with ALA-358B and ILE-361B from
one side, and with LEU-370A from the other side. Regarding compound 2, it revealed a binding mode
and interactions quite similar to that of 1. Such strong interactions with the PK binding side explain the
good in vitro inhibitory activity of both 1 and 2 (Table 4) in comparison to 3, which showed different
binding modes inside the enzyme’s binding cavity. Unlike 1 and 2, and due to its single carboxylic acid
moiety, 3 fitted inside the other corner of the active pocket through only three hydrogen bonds with
ASN-369B and THR-353A. Regarding hydrophobic interactions, it interacted with only two residues,
ALA-358A, and ILE-361A (Figure 6). These weaker interactions explain the inferior in vitro inhibitory
activity of 3 toward PK (Table 4). In addition, it indicates the importance of the 1,6-dicarboxylic acid
moieties in the future development of Staphylococcus PK inhibitors.
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3. Material and Methods
3.1. General Experimental Procedures
The chemical solvents used in this study, such as n-hexane, dichloromethane, ethyl acetate,
and methanol, were obtained from Sigma-Aldrich, Saint Louis, Missouri, USA. Silica gel 60 (63–200 µM,
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E. Merck, Sigma-Aldrich) and Sephadex LH20 (0.25–0.1 mm, GE Healthcare, Sigma-Aldrich) were
used for chromatographic isolation and purification. Thin-layer chromatography was performed using
pre-coated silica gel aluminum plates (E. Merck, Darmstadt, Germany, Kieselgel 60 F254, 20 × 20 cm,
0.25 mm). p-anisaldehyde (0.5 : 85 : 10 : 5 p-anisaldehyde : methanol : glacial acetic acid : sulfuric acid)
was used as visualizing spray reagent for different spots accompanied by heating at 110 ◦C. 1D, 2D,
and 13C NMR spectra were recorded on a JEOL ECA-600 spectrometer (600 MHz for 1H and 150 MHz
for 13C, respectively). Each sample was dissolved in prober deuterated solvent such as CDCl3 and
CD3OD. All of the chemical shifts were recorded and expressed in ppm units related to the TMS signal
as an internal standard, and coupling constants (J) were recorded in Hz.
3.2. Sponge Collection
Callyspongia sp. and Spheciosponge vagabunda were collected from the Red Sea (Ras Mohamed,
Sinai; (GPS coordinates 27◦47.655 N; 34◦12.904 W) at a depth of 10 m in August 2006. The collected
sponges, identified by R.W.M. van Soest (University of Amsterdam, Netherlands), were transferred
to plastic bags containing sterile seawater and transported to the laboratory. Sponge biomass was
cleaned with sterile seawater, cut into fragments of ca. 1 cm3, and then carefully homogenized with 10
volumes of seawater. The freshly prepared supernatant was diluted in 10-fold series (10−1, 10−2, 10−3)
and subsequently plated out onto agar plates.
3.3. Actinomycetes Isolation
Different media were used for isolation of actinomycetes M1 [39]—ISP2 medium [40], oligotrophic
medium [41], and marine agar [42]. The isolation of slow-growing actinomycetes needed all these
different media to be supplemented with nalidixic acid (25 µg/mL), nystatin (25 µg/mL), and 0.2 µM
pore size filtered cycloheximide (100 µg/mL). Nystatin and cycloheximide prevent fungal growth,
while nalidixic acid prevents many fast-growing Gram-negative bacteria [43]. All media consisted of
Difco Bacto agar (18 g/L) and were prepared in 1 L artificial sterile sea water [44]. Micromonospora sp.
UR56 and Actinokinospora sp. EG49 were cultivated on ISP2 medium. The inoculated agar plates were
incubated at 30 ◦C for a long time, ranging from 6 to 8 weeks. Distinct colony morphotypes were
selected and re-streaked many times until free of any contaminants.
3.4. Molecular Identification
16S rRNA gene amplification, cloning, and sequencing were performed using the universal
primers 27F and 1492R according to Hentschel et al. [45]. Chimeric sequences were detected using the
Pintail program [46]. The genus-level affiliation of the sequence was confirmed using the Ribosomal
Database Project Classifier. The genus-level identification of all the sequences was performed using
RDP Classifier (-g 16srrna, -f allrank) and confirmed with the SILVA Incremental Aligner (SINA) (search
and classify option) [47]. An alignment was evaluated again using the SINA web aligner (variability
profile: bacteria). Gap-only positions were removed with trimAL (-noallgaps). For phylogenetic tree
construction, the best fitting model was first estimated using Model Generator. Visualization was
performed using Interactive Tree of Life.
3.5. Microbial Fermentation and Extract Preparation
Micromonospora sp. UR 56 and Actinokineospora sp. EG49 were isolated from Red Sea sponges
Callyspongia sp and Spheciospongia vagabunda, respectively. Each microbial strain was fermented
in 10 Erlenmeyer flasks (2 L), each containing 1 L of ISP2 medium and incubated at 30 ◦C with
shaking (150 rpm) for 14 days. For the co-fermentation experiment, 10 mL of 5 day old culture of
Micromonospora sp. UR56 was transferred into 10 Erlenmeyer flasks (2 L), each containing 1 L of ISP2
medium inoculated with 10 mL of 5 day old culture of Actinokineospora sp. EG49. After fermentation
of axenic cultures and co-culture, filtration was performed, and the supernatant was extracted with
ethyl acetate (1.5 L) to give the ethyl acetate soluble fraction (700 mg).
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3.6. LC-HR/MS Metabolomic Analysis
LC–HR–ESI–MS metabolomics analyses were performed as previously described by
Abdelmohsen et al. [48]. Ethyl acetate soluble fraction 1 mg/mL in MeOH was uploaded and analyzed
using an Accela HPLC (Thermo Fisher Scientific, Karlsruhe, Germany) combined with UV–visible
detector and Exactive-Orbitrap mass spectrometer (Thermo Fisher Scientific, Karlsruhe, Germany)
using an HPLC column (an ACE C18, 75 mm × 3.0 mm, 5 µM column (Hichrom Limited, Reading, UK).
The gradient elution was carried out at 300 µL/min for 30 min using purified water (A) and acetonitrile
(B) with 0.1% formic acid in each mobile phase. The gradient program started with 10% B, increased
gradually to 100% B, and continued isocratic for 5 min before linearly decreasing back to 10% B for
1 min. The total analysis period for each fraction was 45 min. The injection volume was 10 µL and the
column temperature was maintained at 20 ◦C. High-resolution mass spectrometry was performed in
both negative and positive ionization modes with a spray voltage of 4.5 kV and capillary temperature
of 320 ◦C. The mass range was maintained at 150–1500 m/z. All positive and negative ionization files
used to cover the highest number of metabolites were subjected to data mining software MZmine 2.10
(Okinawa Institute of Science and Technology Graduate University, Japan) for deconvolution, peak
picking, alignment, deisotoping, and molecular formula prediction. Dictionary of natural products
(DNP), Marinlit, and METLIN databases were used for identification of all metabolites.
3.7. Isolation and Purification of Induced Metabolites
The crude ethyl acetate (EtOAc) soluble fraction (700 mg, obtained from co-fermentation) was
chromatographed on a Sephadex LH20 (32-64 µM, 100 × 25 mm) column using MeOH/H2O (80 :
20%) to afford five main fractions (Fr.1 - Fr.5). Fr.2 (200 mg) was chromatographed over a silica gel
column (CC). Gradient elution was performed using a gradient mixture of DCM : EtOAc (100 : 0 to 0 :
100) followed by 100% MeOH to afford 13 subfractions. SubFr.5 (30 mg) was further chromatographed
on a Sephadex LH20 using Hex: DCM (50:50) as mobile phase to yield compound 3 (15 mg, 2.14%
crude weight). SubFr.7 was washed several times with DCM, resulting in crystallization and affording
compound 9 (10 mg, 1.42% crude weight). Fr.3 (175 mg) was chromatographed over a silica gel column
with n-hexane: EtOAc (100:0 to 0:100) to yield nine subfractions (Fr.3-1 to Fr.3-9). Fr.3-7 and Fr.3-8
(30 mg and 20 mg) were further chromatographed over Sephadex LH20 using Hex: CH2CL2 (50:50)
as mobile phase to afford pure compounds 1 and 2 (12 mg and 15 mg, 1.71 and 2.14% crude weight),
respectively. Fr.5 (75 mg) was further chromatographed on a Sephadex LH20 using MeOH as mobile
phase to afford pure compound 10 (8 mg, 1.14% crude weight).
3.8. Assessment of Antibacterial Activity
The antibacterial activity of all isolated pure compounds (1–3, 9, and 10) was evaluated on
Gram-positive pathogenic bacteria such as Bacillus subtilis (ATCC29212) and Staphylococcus aureus
(ATCC9144 (and Gram-negative pathogenic bacteria such as Escherichia coli. (ATCC25922) and
Pseudomonas aeruginosa (ATCC27853), as previously reported [49]. The tests were carried out in 96 well
flat polystyrene plates. First, 10 µL of each isolated compound (15 µM) was transferred to 80 µL of
lysogeny broth followed by the addition of 10 µL of bacterial suspension at log phase, and then all
inoculated plates were incubated overnight at 37 ◦C. After incubation, the positive effect of the tested
compounds was detected as clearance in the wells, and in compounds that showed no activity on the
bacteria, the growth medium in the wells seemed opaque. The absorbance was observed after 20 h at
OD600 in a Spectrostar Nano Microplate Reader (BMG LABTECH GmbH, Allmendgrun, Germany).
The positive control was pathogenic bacteria plus distilled water, while the negative control was
growth medium plus distilled water.
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3.9. Assessment of Antibiofilm Activity
The biofilm-inhibitory activities of the isolated pure compounds (1–3, 9, and 10) were
measured using 96 well flat polystyrene plates against four clinical microbes comprising
Gram-positive (Bacillus subtilis and Staphylococcus aureus) and Gram-negative (Escherichia coli and
Pseudomonas aeruginosa) pathogenic bacteria, according to Antunes, et al. [50] with some modifications.
Briefly, each well was filled with 180 µL lysogeny broth (LB broth) and then inoculated with 10 µL
of pathogenic bacteria followed by addition of 10 µL of sample (2 µM) along with control (without
test sample). All inoculated plates were then incubated overnight at 37 ◦C and, after incubation,
content in the wells was removed and wells were rinsed with 200 µL of phosphate-buffered saline
(PBS) pH 7.2 to eliminate free-floating microbes and left to dry under sterilized laminar flow for 1 h.
For staining, 200 µL/well of crystal violet (0.1%, w/v) was added, left for 1 h, and then excessive stain
was removed and plates retained for drying. Further, dried plates were rinsed with 95% ethanol and
optical density was measured at 570 nm using a Spectrostar Nano Microplate Reader (BMG LABTECH
GmbH, Allmendgrun, Germany).
3.10. Assessment of Cytotoxic Activity
MTT Assay
This assay was performed using different human cancer cell lines, including mammary gland breast
cancer (MCF-7), colorectal carcinoma (HCT-116), human lung cancer cell line (WI38), and hepatocellular
carcinoma (HePG-2). The cell lines were purchased from ATCC by (VACSERA), Cairo, Egypt.
Doxorubicin was used as a positive control drug. The cell lines were used to detect the inhibitory effects
of isolated compounds on cell growth. Cell viability was determined via colorimetric assay (MTT),
which is based on the transformation of the yellow tetrazolium bromide to a purple formazan by
mitochondrial succinate dehydrogenase. Cell lines were cultivated in rpmI-1640 medium supplemented
with 10% fetal bovine serum, 100 units/mL penicillin, and 100 µg/mL streptomycin incubated at 37 ◦C
under 5% CO2. The cell lines were plated in a 96 well microtiter plate at a concentration of 1.0 × 104
cells/well and incubated at 37 ◦C under 5% CO2 for 2 days. Subsequently, the cells were mixed with
different concentrations of the isolated compounds and incubated for a further 24 h, and then treated
with 20 µL of MTT solution at a concentration of 5 mg/mL and incubated for 4 h. The purple formazan
precipitates were dissolved in 100 µL of dimethyl sulfoxide (DMSO) and the optical density for each
well was measured and recorded at an absorbance of 570 nm using a plate reader (EXL 800, Biotek®,
Winooski, Vermont, USA). The relative cell viability as a percentage was calculated as A570 of treated
samples/A570 of untreated sample × 100.
3.11. Enzyme Assays
DNA gyrase (type II topoisomerase) and topoisomerase IV (ParE) add negative supercoils into
DNA using ATP hydrolysis as a source of energy. They are considered crucial bacterial enzymes
that are absent in eukaryotes. DNA-gyrase-B- and ParE-inhibitory activities were evaluated using
the Inspiralis assay kit (Inspiralis®, London, UK) on streptavidin-coated 96 well microtiter plates
(Thermo Scientific, Hamburg, Germany), according to the manufacturer’s protocol [51]. The assay
detects the ability of the isolated compounds to prevent the ATPase activity of both gyrase-B and ParE
subunits. On the other hand, pyruvate kinase (PK) has been discovered to be an important hub protein
in the interactome of MRSA [52]. The PK-inhibitory activity of the isolated compounds was assessed
according to a previously reported method [53].
3.12. Docking Analysis
Staphylococcus Gyr-B and PK crystal structures with the of PDB codes 3g7b and 3T0T, respectively,
were used. Docking experiments were performed using AutoDock Vina docking software [54].
Such docking engines deal with the receptor as a rigid structure and the ligand as a flexible structure
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during their calculations. The co-crystallized ligands were utilized to assign the binding sites.
The ligand-to-binding-site shape-matching root mean square threshold was set to 2.0 Å. The interaction
energies were determined using the Charmm force field (CFF) (v.1.02) with 10.0 Å as a non-bonded
cutoff distance and distance-dependent dielectric. Subsequently, 5.0 Å was set as an energy grid
extending from the binding site. The tested compounds were energy-minimized inside the selected
binding pocket. The editing and visualization of the generated binding poses were performed using
Pymol 2.3 software (Schrödinger, München, Germany).
3.13. Structuraal Elucidation of Isolated Compounds 1–3, 9, and 10.
The structures of the known induced metabolites were confirmed by comparison of their
spectroscopic (HRMS and 1H, 13C and 2D-NMR) data with the published literature data as
1, dimethylphenazine-1,6-dicarboxylate [55]; 2, phencomycin [55–57]; 3, tubermycinB [57–60];
9, N-(2-hydroxyphenyl)-acetamide [24,56]; and 10, p-anisamide [61].
4. Conclusions
Actinomycetes genomes, in particular the order Actinomycetales, consist of numerous biosynthetic
gene clusters encoding for secondary metabolites that have not yet been detected under standard
laboratory conditions, and that need to be cultivated using elicitation approaches such as co-cultivation.
In the present work, two Red-Sea-sponge-associated actinomycetes, Micromonospora sp. UR56 and
Actinokineospora sp. EG49, were subjected to co-cultivation. Metabolomic profiling of both axenic
actinomycetes and their co-culture revealed that the latter was more diverse in its induced metabolites
profile, particularly in terms of phenazine derivatives. After isolation of the major induced metabolites
(1–3, 9, and 10), their possible antibacterial, antibiofilm, and cytotoxic activities were assessed.
Phenazine derivatives 1–3 were significantly active as antibacterial and antibiofilm agents with
mild cytotoxicity. Subsequently, they were tested against Gyr-B and PK as possible molecular
targets. The presence of carboxylic acid or an ester moiety at C-1 and C-6 was found to be crucial
for the activity spectra of these compounds, where the antibacterial and antibiofilm effects were
flipped from Gram-positive to Gram-negative strains, and their enzyme-inhibitory activities were
significantly decreased upon removal of either carboxylic acid or the ester moiety at C-6. These findings
could represent a good starting point from which to develop further phenazine-based antibiotics.
Additionally, they highlight microbial mixed fermentation as a simple and effective approach to produce
new antimicrobial agents through the induction of otherwise cryptic bacterial biogenetic pathways.
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